Intestinal transplantation: Current outcomes and opportunities

Current Opinion in Organ Transplantation

Volumn 14, Issue 5, 2009, Pages 515-521

  Mazariegos, George V ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Immune and allograft monitoring; Intestinal rehabilitation; Intestine failure; Outcomes; Transplantation

Indexed keywords

MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

CHILD; CHRONIC GRAFT REJECTION; GENOMICS; GRAFT FAILURE; HUMAN; INTESTINE ADAPTATION; INTESTINE TRANSPLANTATION; KIDNEY DYSFUNCTION; MORBIDITY; OUTCOMES RESEARCH; PATIENT MONITORING; PATIENT REFERRAL; PEDIATRIC SURGERY; POSTOPERATIVE COMPLICATION; PROTEOMICS; REHABILITATION CARE; REVIEW; SURVIVAL RATE; TREATMENT INDICATION;

DONOR SELECTION; HUMANS; INTESTINAL DISEASES; INTESTINES; ORGAN TRANSPLANTATION; TREATMENT OUTCOME; WAITING LISTS;

EID: 73349134955     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328330680d     Document Type: Review

References (52)

1. Nucci A, Burns RC, Armah T, et al. Interdisciplinary management of pediatric intestinal failure: a 10-year review of rehabilitation and transplantation. J Gastrointest Surg 2008; 12:429-435; discussion 435-1426
2. Beath S, Pironi L, Gabe S, et al. Collaborative strategies to reduce mortality and morbidity in patients with chronic intestinal failure including those who are referred for small bowel transplantation. Transplantation 2008; 85:1378-1384. The authors summarize a consensus workshop defining critical issues in patients with chronic intestinal failure. Among the conclusions was a need for establishment of a national intestinal failure registry and the need to optimize timing for referral for rehabilitation and/or transplantation.
3. Sudan D, DiBaise J, Torres C, et al. A multidisciplinary approach to the treatment of intestinal failure. J Gastrointest Surg 2005; 9:165-176; discussion 176-1167
4. Iyer KR, Horslen S, Torres C, et al. Functional liver recovery parallels autologous gut salvage in short bowel syndrome. J Pediatr Surg 2004; 39:340-344; discussion 340-344.
5. Spencer AU, Neaga A, West B, et al. Pediatric short bowel syndrome: redefining predictors of success. Ann Surg 2005; 242:403-409; discussion 409-412.
6. Goulet O, Baglin-Gobet S, Talbotec C, et al. Outcome and long-term growth after extensive small bowel resection in the neonatal period: a survey of 87 children. Eur J Pediatr Surg 2005; 15:95-101.
7. Quiros-Tejeira RE, Ament ME, Reyen L, N et al. Long-term parenteral nutritional support and intestinal adaptation in children with short bowel syndrome: a 25-year experience. The Journal of pediatrics 2004; 145:157-163.
8. Farmer DG, Venick RS. Morbidity and mortality associated with chronic intestinal failure. Transplantation 2008; 85:1385-1386.
9. Wiles A, Woodward JM. Recent advances in the management of intestinal failure-associated liver disease. Curr Opin Clin Nutr Metab Care 2009; 12:265-272.
10. Diamond IR, Sterescu A, Pencharz PB, et al. Changing the paradigm: omegaven for the treatment of liver failure in pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr 2009; 48:209-215.
11. Gura KM, Lee S, Valim C, et al. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics 2008; 121:e678-e686.
12. Gura KM, Duggan CP, Collier SB, et al. Reversal of parenteral nutritionassociated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics 2006; 118:e197-e201.
13. Ching YA, Fitzgibbons S, Valim C, et al. Long-term nutritional and clinical outcomes after serial transverse enteroplasty at a single institution. J Pediatr Surg 2009; 44:939-943.
14. Kocoshis SA, Beath SV, Booth IW, et al. Intestinal failure and small bowel transplantation, including clinical nutrition: Working Group report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2004; 39 (Suppl 2):S655-S661.
15. Berg CL, Steffick DE, Edwards EB, et al. Liver and intestine transplantation in the United States 1998-2007. Am J Transplant 2009; 9 (4 Pt 2):907-931. This article provides an up-to-date analysis of intestinal transplant candidates and recipients in the USA.
16. Fryer J, Pellar S, Ormond D, et al. Mortality in candidates waiting for combined liver-intestine transplants exceeds that for other candidates waiting for liver transplants. Liver Transpl 2003; 9:748-753.
17. Chungfat N, Dixler I, Cohran V, et al. Impact of parenteral nutrition-associated liver disease on intestinal transplant waitlist dynamics. J Am Coll Surg 2007; 205:755-761.
18. Mian SI, Dutta S, Le B, et al. Factors affecting survival to intestinal transplantation in the very young pediatric patient. Transplantation 2008; 85:1287-1289.
19. Abu-Elmagd K, Fung J, Bueno J, et al. Logistics and technique for procurement of intestinal, pancreatic, and hepatic grafts from the same donor. Ann Surg 2000; 232:680-687.
20. Bueno J, Abu-Elmagd K, Mazariegos G, et al. Composite liver: small bowel allografts with preservation of donor duodenum and hepatic biliary system in children. J Pediatr Surg 2000; 35:291-295; discussion 295-296.
21. Matsumoto CS, Kaufman SS, Girlanda R, et al. Utilization of donors who have suffered cardiopulmonary arrest and resuscitation in intestinal transplantation. Transplantation 2008; 86:941-946. Deceased donors suffering from cardiac arrest were analyzed for outcomes in intestinal transplant. Mean CPR duration of 19 min was not associated with detriment to survival, length of stay, or rejection as compared with donors not requiring resuscitation.
22. Fryer JP, Iyer K. Innovative approaches to improving organ availability for small bowel transplant candidates. Gastroenterology 2006; 130 (2 Suppl 1): S152-S157.
23. Grevious MA, Iqbal R, Raofi V, et al. Staged approach for abdominal wound closure following combined liver and intestinal transplantation from living donors in pediatric patients. Pediatr Transplant 2009; 13:177-181.
24. Zanfi C, Cescon M, Lauro A, et al. Incidence and management of abdominal closure-related complications in adult intestinal transplantation. Transplantation 2008; 85:1607-1609.
25. Carlsen BT, Farmer DG, Busuttil RW, et al. Incidence and management of abdominal wall defects after intestinal and multivisceral transplantation. Plast Reconstr Surg 2007; 119:1247-1255; discussion 1256-11248
26. Kato T, Selvaggi G, Gaynor JJ, et al. Inclusion of donor colon and ileocecal valve in intestinal transplantation. Transplantation 2008; 86:293-297.
27. Testa G, Holterman M, Abcarian H, et al. Simultaneous or sequential combined living donor-intestine transplantation in children. Transplantation 2008; 85:713-717.
28. Benedetti E, Holterman M, Asolati M, et al. Living related segmental bowel transplantation: from experimental to standardized procedure. Ann Surg 2006; 244:694-699.
29. Testa G, Holterman M, John E, et al. E. Combined living donor liver/small bowel transplantation. Transplantation 2005; 79:1401-1404. (Pubitemid 40734804)
30. Gangemi A, Tzvetanov IG, Beatty E, et al. Lessons learned in pediatric small bowel and liver transplantation from living-related donors. Transplantation 2009; 87:1027-1030.
31. Noguchi Si S, Reyes J, Mazariegos GV, et al. Pediatric intestinal transplantation: the resected allograft. Pediatr Dev Pathol 2002; 5:3-21. (Pubitemid 34279694)
32. Grant D. Accessed by request at www.IntestineTransplant.org January 2009.
33. Mazariegos GV, Soltys K, Bond G, et al. Pediatric intestinal retransplantation: techniques, management, and outcomes. Transplantation 2008; 86:1777-1782.
34. Pirenne J. Intestinal transplantation: evolution in immunosuppression protocols. Current opinion in organ transplantation 2009; 4:250-255.
35. Abu-Elmagd KM, Costa G, Bond GJ, et al. Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance. Transpl Int 2009; 22(1Special Review Issue: Minimization of Immunosuppression): 96-109.
36. Reyes J, Mazariegos GV, Abu-Elmagd K, et al. Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit antithymocyte globulin (thymoglobulin). Am J Transplant 2005; 5:1430-1436.
37. Tzakis AG, Kato T, Nishida S, et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation 2003; 75:1512-1517.
38. Tzakis AG, Kato T, Nishida S, et al. Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. Transplantation 2003; 75:1227-1231.
39. Ashokkumar C, Talukdar A, Sun Q, et al. Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. Am J Transplant 2009; 9:179-191.
40. Zeevi A, Britz JA, Bentlejewski CA, et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transpl Immunol 2005; 15:17-24.
41. Fishbein T, Novitskiy G, Mishra L, et al. NOD2-expressing bone marrowderived cells appear to regulate epithelial innate immunity of the transplanted human small intestine. Gut 2008; 57:323-330. Predicting immunologic risk in intestinal transplant recipients may help guide management and improve outcomes. In this report, mutant NOD2 alleles were associated with an increased chance of allograft failure in transplant recipients. The authors hypothesize that NOD2-expressing cells may be involved in epithelial defense mechanisms.
42. Kato T, Mizutani K, Terasaki P, et al. Association of emergence of HLA antibody and acute rejection in intestinal transplant recipients: a possible evidence of acute humoral sensitization. Transplant Proc 2006; 38:1735-1737.
43. Wu T, Abu-Elmagd K, Bond G, Demetris AJ. A clinicopathologic study of isolated intestinal allografts with preformed IgG lymphocytotoxic antibodies. Hum Pathol 2004; 35:1332-1339.
44. de Serre NP, Canioni D, Lacaille F, et al. Evaluation of c4d deposition and circulating antibody in small bowel transplantation. Am J Transplant 2008; 8:1290-1296.
45. David AI, Selvaggi G, Ruiz P, et al. Blood citrulline level is an exclusionary marker for significant acute rejection after intestinal transplantation. Transplantation 2007; 84:1077-1081.
46. Gondolesi G, Ghirardo S, Raymond K, et al. The value of plasma citrulline to predict mucosal injury in intestinal allografts. Am J Transplant 2006; 6:2786-2790.
47. Yu HC, Tuteja S, Moon JI, et al. Utilization of dried blood spot citrulline level as a noninvasive method for monitoring graft function following intestinal transplantation. Transplantation 2005; 80:1729-1733.
48. Sudan D, Vargas L, Sun Y, et al. Calprotectin: a novel noninvasive marker for intestinal allograft monitoring. Ann Surg 2007; 246:311-315.
49. Akpinar E, Vargas J, Kato T, et al. Fecal calprotectin level measurements in small bowel allograftmonitoring: a pilot study. Transplantation2008;85:1281- 1286.
50. Altimari A, Gruppioni E, Capizzi E, et al. Blood monitoring of granzyme B and perforin expression after intestinal transplantation: considerations on clinical relevance. Transplantation 2008; 85:1778-1783.
51. Lacaille F, Vass N, Sauvat F, et al. Long-term outcome, growth and digestive function in children 2 to 18 years after intestinal transplantation. Gut 2008; 57:455-461.
52. Sudan D, Horslen S, Botha J, et al. Quality of life after pediatric intestinal transplantation: the perception of pediatric recipients and their parents. Am J Transplant 2004; 4:407-413.